Promoting immune tolerance to transplanted organs can minimize the amount of
immunosuppressive drugs that patients need to take, reducing lifetime risks of mortality and …

Immunosuppression after liver transplantation is essential for preventing allograft rejection.
However, long-term drug toxicity and associated complications necessitate investigation of …

Donor-derived cell-free DNA (dd-cfDNA) has been evaluated as a rejection marker in organ
transplantation. This study sought to assess the utility of dd-cfDNA to diagnose graft injury in …

Tumor recurrence after liver transplantation has been linked to multiple factors, including the
recipient's tumor burden, donor factors, and ischemia-reperfusion injury (IRI). The increasing …

Graft survival beyond year 1 has not changed after orthotopic liver transplantation (OLT)
over the last decades. Likewise, OLT causes comorbidities such as infection, renal …

Personalized immunosuppression (IS) promises to improve the balance of necessary control
of alloreactivity and dose‐dependent adverse effects of long‐term IS such as kidney …

Liver-resident CD56brightCD16-natural killer (NK) cells are enriched in the human liver and
are phenotypically distinct from their blood counterparts. Although these cells are capable of …

The liver is considered a tolerogenic organ that can induce peripheral tolerance. The exact
mechanisms of tolerance in the liver remain undefined. Regulatory T cells (Tregs) have …

Spontaneous operational tolerance to the allograft develops in a proportion of liver
transplantation (LT) recipients weaned off immunosuppressive (IS) drugs. Several studies …

Simple Summary Long-term immunosuppressive therapy following liver transplantation is
associated with an increased risk for the development of de novo lung carcinoma. However …